INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) provides today an overview of data presented during the 51st Annual Meeting of the American Society of Hematology (“ASH”)

Transparency directive : regulatory news

07/12/2009 06:50

PRESS RELEASE

NEW DATA PRESENTED AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY
("ASH")

Updated Phase II interim results with IPH 1101 in non-Hodgkin's lymphoma on
  a larger cohort con firming encouraging trend in complete response rate
Update on IPH 2101 Phase I trials and new set of pre-clinical data
Innate Pharma's lead drug-candidates presented during two oral and five
  posters sessions, rein forcing the Company's presence in the hemato-oncology
  scientific and medical communities

Marseilles, France, December 7, 2009

Innate Pharma (the "Company" - Euronext Paris: FR0010331421 - IPH) provides
today an overview of data presented during the 51st Annual Meeting of the
American Society of Hematology ("ASH"), taking place on December 5-8, 2009 in
New Orleans, LA, with notably updated Phase II interim data with IPH 1101 in
non-Hodgkin's lymphoma, as well as an update on IHP 2101 Phase I trials.

Poster #1649, presented by Guy Laurent, MD (Hemato-Oncology department, CHU
Purpan, Toulouse, France), co-lead investigator of the trial, notably reports
updated interim clinical data with IPH 1101 in combination with rituximab
(Mabthera/Rituxan(r)) in non-Hodgkin's lymphoma patients. On the first 34
evaluable patients assessed by independent central review, 16 patients showed a
response (i.e. 47% Overall Response Rate, or "ORR"), including 11 patients
showing a complete response (i.e. 32% Complete Response Rate or "CRR"). The
complete response rate observed with standard of care (rituximab alone) in
similar settings is 11% CRR(1). Final data on all evaluable patients are
expected by mid-2010.

Poster detailing these results can be downloaded on Innate Pharma's website
(www.innatepharma.com).

"The level of responses, and especially the rate of complete responses, seen in
this population of patients already exposed to prior lines of standard
treatments, including rituximab, is very encouraging. It supports the concept of
this well tolerated combined immunotherapy approach with IPH 1101 as a new
therapeutic option in Follicular Lymphoma patients", said Pr Jean-François
Rossi (Head of Hemato-Oncology Department and Center of Clinical Investigation
BT 509, University Hospital, Montpellier, France), co-lead investigator of the
trial.

Innate Pharma's lead drug-candidates, IPH 2101 and IPH 1101, are also presented
in two oral sessions on Monday, December 7:

- The first one presents immuno-biological results from the Phase II study
  combining IPH 1101 and rituximab in non-Hodgkin's lymphoma: "IPH 1101, the
  First Specific gama delta T Cell Agonist, Shows Potent Immuno-Biological
  Efficacy in Low Grade Follicular Lymphoma Patients When Combined with
  Rituximab: Results From a Phase II Study", presented by Dr. Hélène Sicard,
  PhD, Head of the IPH 1101 program at Innate Pharma.

- The second one reports end of Phase I dose escalation trial with IPH 2101 in
  Acute Myeloid Leu kemia: "A Phase I Study of the Anti-Natural Killer
  Inhibitory Receptor (KIR) Monoclonal Antibody (1-7F9, IPH 2101) in Elderly
  Patients with Acute Myeloid Leukemia (AML): Clinical and Immunological
  Effects of a Single Dose Followed by Repeated Dosing", presented by Dr.
  Norbert Vey, MD (Institut Paoli Calmettes, Marseille), lead investigator of
  the trial. This trial has now progressed to an extension study in the same
  patient population.

(1) Davis et al., Journal of Clinical Oncology, 2000

Study progresses as well as pre-clinical data from international collaborations
with IPH 2101, are also presented notably in Posters #2880 and #3870:

- Poster #2880, presented by Don Benson, MD, PhD (Division of
  Hematology/Oncology, Ohio State Cancer Center, Columbus, OH), reporting
  Phase I study progress with IPH 2101 in multiple myeloma ("MMy"): the study
  escalation part has been completed with good tolerance of the drug candidate
  in this setting. It has now progressed to an extension phase testing the
  highest dose level of IPH 2101 in 7 additional patients presenting a
  lessadvanced disease. Don Benson, presenting this poster, was interviewed by
  the International Myeloma Foundation (IMF) as one of the investigators
  presenting the most interesting and important studies in myeloma at the 2009
  ASH meeting.

- Poster #3870, presented by Sherif Farag, MBBS, PhD (Indiana University School
  of Medicine, Indianapolis, IN), and Don Benson, MD, PhD (Division of
  Hematology/Oncology, Ohio State Cancer Center, Columbus, OH), describing
  pre-clinical data on the combination of IPH 2101 and lenalidomide
  (Revlimid(r)) in MMy. These data supports the upcoming trial testing this
  combination in MMy patients who have failed first-line therapy. As previously
  announced, Innate Pharma will benefit from Celgene's collaboration for this
  trial.

"ASH is a very important meeting for us as Innate Pharma is a company with a
strong clinical development focus in onco-hematology", said Dr. Patrick Squiban,
CMO of Innate Pharma. He added: "With two oral presentations and data from
international collaborations, we have presentation of significant data at ASH
this year that further validates the relevance and the maturation of our
programs"

About Innate Pharma:

Innate Pharma S.A. ("the company") is a clinical-stage biopharmaceutical company
developing first-in-class immunotherapy drugs for cancer and other severe
diseases. The company was incorporated in 1999 and listed on NYSE-Euronext in
Paris in 2006.

Innate Pharma currently has seven proprietary drug candidates in development
(two of which are in Phase II clinical trials) and two programs out-licensed to
Novo Nordisk A/S.

Innate Pharma is based in Marseilles, France, and had 84 employees as at
September 30, 2009.

Learn more about Innate-Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code     FR0010331421
Ticker code   IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference prospectus
filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                  Alize Public Relations
Laure-Hélène Mercier,          Caroline Carmagnol
Director, Investor Relations   Phone: +33 (0)1 41 22 07 31
Phone: +33 (0)4 30 30 30 87    Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.fr     caroline@alizerp.com

091207_ASH

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) provides today an overview of data presented during the 51st Annual Meeting of the American Society of Hematology (“ASH”)

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories